A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced By Moderately Emetogenic Chemotherapy
Latest Information Update: 05 Sep 2023
At a glance
- Drugs Casopitant (Primary) ; Casopitant (Primary) ; Dexamethasone; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 05 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 01 Jun 2012 Inclusion and exclusion criteria amended as reported by ClinicalTrials.gov.
- 20 May 2011 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.